Turmoil at CBER: Peter Marks grabs control of FDA's Office of Vaccines ahead of 2 key career leader departures

Zachary Brennan

Senior Editor

FDA’s top vaccine official Peter Marks is pulling the plug on a months-long transition for two top career vaccine officials who abruptly called it quits …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Turmoil at CBER: Peter Marks grabs control of FDA's Office of Vaccines ahead of 2 key career leader departures

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

FDA updates label of 33-year-old cancer drug with new dose and warning

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Are programs with compounded GLP-1s safe for your population?

Tur­moil at CBER: Pe­ter Marks grabs con­trol of FDA's Of­fice of Vac­cines ahead of 2 key ca­reer leader de­par­tures

Zachary Brennan

Senior Editor

Sign up to read this article for free.

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Turmoil at CBER: Peter Marks grabs control of FDA's Office of Vaccines ahead of 2 key career leader departures

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

FDA updates label of 33-year-old cancer drug with new dose and warning

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Are programs with compounded GLP-1s safe for your population?